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Abstract
A panel of murine IgG monoclonal antibodies (MAbs) was produced against coxsackievirus A9 (CAV9). Fifty-nine MAbs reactive in ELISA
with purified CAV9 were identified. Eighteen of them could efficiently inhibit infection by CAV9 but not coxsackieviruses B. Neutralization-
resistant CAV9 variants to four different MAbs were isolated and tested for resistance to neutralization by other MAbs of the panel. Three groups
of reactivity including 10, 7, and 1 MAbs were thus identified. Sequencing of neutralization-escape virus mutants showed that neutralization by
one MAb group was affected by change of VP3 amino acids 62 or 69. For the second group of reactivity, mutations included amino acids 154
or 165 of VP2. The only MAb of the third group selected for a change at residue 70 of VP2. Protection studies in a newborn mouse model of
myositis suggested that either epitopes in VP2 or in VP3 mediate protection from CAV9 infection in vivo.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Enteroviruses are responsible for a wide range of human
diseases, including poliomyelitis and other infections of the
central nervous system, myocarditis, rashes, and respiratory
infections, and there is evidence of their role in the devel-
opment of insulin-dependent diabetes mellitus (IDDM)
(Grist et al., 1978; Hovi et al., 1996; Hyoty et al., 1995).
With the progression toward global poliovirus eradication,
other clinically important members of the genus enterovirus
are increasingly attracting the interest of scientists largely
because research achievements on the widely studied polio-
viruses might help establish effective prophylactic mea-
sures. Among these pathogens is coxsackievirus A9
(CAV9), which can cause infections varying from common
cold to fatal infections of the central nervous system (Grist
et al., 1978; Kinnunen et al., 1987). Together with coxsackie
B viruses, CAV9 is also implicated in the etiology of IDDM
(Hyoty et al., 1995; Roivainen et al., 1998), a disease oc-
curring frequently worldwide and leading patients to serious
physical impairment and need for continuous therapy. Dia-
betes is not a normal outcome of CAV9 infection, and
genetic and other factors are involved, such as certain HLA
types and autoimmune disease and molecular mimicry
(D’Alessio, 1992; Chatterjee, 1994; Baum et al., 1995).
Similar to the other enteroviruses which belong to the
Picornaviridae family, CAV9 is a nonenveloped single-
stranded RNA virus with an icosahedral capsid made of 60
copies each of four polypeptides, VP1 through 4 (Hendry et
al., 1999). In CAV9, VP1 contains at its C-terminus a
functional RGD-motif reacting with v3-integrin during
early virus–cell interactions (Roivainen et al., 1991, 1994),
although the virus can also use an RGD-independent mode
of entry (Hughes et al., 1995; Roivainen et al., 1996; Tri-
antafilou et al., 1999). Despite the structural similarities
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with poliovirus, there is no conclusive evidence so far that
the same regions in the capsid antigens of CAV9 would
react with the host immune system eliciting neutralizing
antibodies. A detailed map of neutralization determinants
has been developed for all three types of poliovirus by
characterization of wide panels of monoclonal antibodies
(MAbs) and sequence analysis of neutralization-escape vi-
rus variants (Blondel et al., 1986; Diamond et al., 1985;
Minor et al., 1985, 1986; Page et al., 1988; Wiegers et al.,
1989, 1990). Complex epitopes, termed N-AgI through V,
have thus been recognized involving amino acid regions of
VP1, VP2, and VP3. Matching the results of these analyses
with those of X-ray crystallographic studies has made it
possible to identify the neutralization sites in the three-
dimensional structure of the virion (Filman et al., 1989;
Hogle et al., 1985). Participating in at least four of the sites
known, VP1 appears to play a major role in the organization
of poliovirus neutralization antigens, correlating well with
its exposed position on the virion surface.
A recent antigenic analysis of CAV9 performed with
polyclonal hyperimmune sera and a peptide scanning tech-
nique has revealed the presence of at least two immuno-
genic regions in VP1, one in VP2 and one in VP3 (Pulli et
al., 1998a). Further studies of the C-terminal part of VP1
using peptide-specific antisera suggested a possible role of
this region in virus neutralization (Pulli et al., 1998b). In-
terestingly, the most active amino acid region of CAV9 VP1
eliciting a neutralizing response appeared to include resi-
dues 293 through 302, which in poliovirus are adjacent to
the VP1 moiety of N-AgIII (Page et al., 1988; Wiegers et
al., 1990), suggesting that these viruses may share a similar
molecular mechanism for neutralization. More recently, the
determination of the atomic structure of CAV9 has shown
that the RGD motif is located in a flexible extension on the
south side of the “canyon,” which for several members of
the picornavirus family acts as the major site for attachment
to cells (Hendry et al., 1999). To investigate these aspects
further and to describe a more detailed map of CAV9
epitopes involved in antibody-mediated neutralization, we
developed and characterized a library of monoclonal anti-
bodies raised upon intraperitoneal inoculation of mice. Viral
mutants resistant to neutralization by MAbs were selected,
and their genome was sequenced to identify the mutations
responsible for resistance and locate the antibody binding
sites on the viral capsid proteins. Protection studies in new-
born mice were performed to evaluate a possible activity of
MAbs in protecting from CAV9 infection in vivo.
Results
Development of immunity to CAV9 in mice and
hybridoma screening
Immune response to ip inoculation of mice with 105 PFU
of CAV9 (Griggs strain) was monitored by determining
antiviral neutralizing antibodies in the sera collected after
each antigen boost. Neutralizing antibody titers to CAV9
after the fourth inoculum ranged from 1:128 to 1:1024
among different animals (average Nt titer, 1:512). A mouse
with high-antibody titer was used for fusion and hybridomas
were screened by both neutralization in RD cells and ELISA
assays. From 2  108 spleen cells yielding approximately
1500 vital clones, 53 original cell supernatants showed
reactivity in ELISA and 16 were positive in a neutralization
assay against CAV9. All neutralizing MAbs were also pos-
itive by ELISA and were confirmed to be IgG by an iso-
typing ELISA assay using class- and subclass-specific an-
tisera to mouse immunoglobulins; no IgM antibody-
producing clone was obtained. Two further neutralizing
MAbs of six ELISA-positive clones were obtained from a
second mouse fused separately. Hybridomas secreting neu-
tralizing MAbs were recloned two to three times, and es-
tablished antibodies were named K1 through K16 (first
mouse), 6G11, and 4B3 (second mouse). All ELISA-posi-
tive MAbs were subsequently tested by a second neutral-
ization assay on A549 cells, since these cells would allow us
to recognize possible VP1 MAbs interfering with RGD-
mediated virus binding, which might go undetected in the
RD cell line. In fact, infection of A549 cells by CAV9 is
dependent on the RGD motif, whereas RD cells can also be
infected with mutants where this motif has been deleted
(Hughes et al., 1995; Roivainen et al., 1996). However,
none of the nonneutralizing MAbs in RD cells disclosed
neutralizing activity toward CAV9 in this second assay.
Isolation of neutralization-escape CAV9 mutants
To characterize in detail the viral epitopes recognized by
the neutralizing IgG antibodies obtained, CAV9 variants
resistant to neutralization by single antibodies were selected
by isolation of viral plaques from RD cell monolayers
infected with CAV9 in the presence of antibody. All iso-
lated variants could be grown to similar titers as parental
CAV9 during subsequent replication cycles in cell cultures,
and all isolated variants retained their resistance character-
istics upon passage in cell cultures.
Neutralization analysis of neutralization-escape mutants
and other viruses with MAbs
CAV9 natural mutants resistant to neutralization by
MAbs were isolated to analyze the epitope specificity of the
MAb panel obtained. Cross-neutralization tests performed
with mutants vK3, vK6, vK8, and v4B3 corresponding to
selecting MAbs K3, K6, K8, and 4B3 and the entire panel
of MAbs developed allowed us to identify three different
groups of reactivity among the 18 antibodies. In fact, MAbs
K2, K3, K5, K7, K12, K16, and 6G11 (group 1) neutralized
vK6, vK8, and v4B3 but not mutant vK3. Conversely,
MAbs K1, K4, K6, K8, K9, K10, K11, K13, K14, and K15
(group 2) fully neutralized variants vK3 and v4B3, whereas
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they had no effect on replication of mutants vK6 and vK8.
Finally, MAb 4B3 neutralized the entire panel of variants
except v4B3, so defining a distinct reactivity group (group
3). These results clearly indicated that the three antibody
groups recognized three distinct epitopes spatially well sep-
arated on the virion. At the dilution used in this assay, all
MAbs were able to efficiently neutralize the wild CAV9.
MAbs K3, K6, and 4B3, representative of the three
groups, also neutralized the deletion mutant CAV9d12 in
RD cells. Because CAV9d12 grew poorly on A549 cells,
these assays were not performed. In cross-neutralization
experiments with different human picornaviruses, MAbs
K3, K6, and 4B3 neither neutralized coxsackie B viruses,
serotypes 1 to 6, nor EV1 and HPEV1.
Sequence analysis of neutralization-escape mutants
To investigate the protein specificity of the MAbs and to
locate their binding site along the amino acid sequence and
three-dimensional structure of CAV9, the virus variants
isolated were subjected to nucleotide sequence analysis of
the region encoding the capsid proteins (Table 1). The gene
sequences determined for each mutant were compared with
the sequence of the parental Griggs strain. To verify
whether different mutations could be responsible for resis-
tance to neutralization by the MAbs, viruses from several
distinct plaques were picked from each selection plate,
grown, and further purified separately before sequence anal-
ysis. Five variants selected against group 1 MAb K3, and
eight variants derived from either MAbs K6 or K8 (group
2), were sequenced. Only one variant could be selected from
group 3 MAb 4B3. As shown in Table 1, distinct neutral-
ization-escape virus variants from both K6 and K8 MAbs
showed either one of two base mutations, i.e., at nucleotide
residues 1410 (G  A) or 1443 (A  G). These corre-
sponded to amino acid changes in VP2, at locations 154
(Glu Lys) and 165 (Lys Glu), respectively. Differently,
mutations identified in vK3 were at nucleotide residues
1917 (A  G) or 1938 (A  G), corresponding to amino
acid changes in VP3, site 62 (Thre  Ala) or 69 (Arg 
Gly), respectively. The virus variant to MAb 4B3 presented
a mutation at position 1159 (A  T) corresponding to
replacement of lysine with methionine at site 70 in VP2.
None of the variants was shown to harbor mutations in VP1.
Analysis of hybridoma supernatants or immune sera with
CAV9 or VP1 peptides by ELISA
To investigate the apparent lack of immunogenicity of
the VP1 N-terminus, we analyzed the hybridoma cell su-
pernatants and the sera from mice immunized for MAbs
production with immunogenic synthetic peptides corre-
sponding to the flanking regions of the VP1 RGD motif
(Pulli et al., 1998b), by ELISA. Sera from rabbits immu-
nized against CAV9 or the VP1 peptides were also included.
The results of these assays are reported in Table 2. None of
the cell supernatants reacted with any peptide, whereas the
serum from the mouse used for the first fusion, named
M-CAV9, showed a weak antibody response against pep-
tide 189, downstream of the RGD sequence.
Three-dimensional location of coxsackievirus A9
neutralization sites
A three-dimensional representation of the CAV9 pro-
tomer is shown in Fig. 1. The yellow spheres in the image
identify the positions of amino acids 62 and 69 of VP3,
corresponding to the mutations of CAV9 variants escaping
neutralization by MAb K3, whereas the orange spheres
indicate VP2 amino acids 154 and 165, changed in mutants
selected by both MAbs K6 and K8. The violet sphere shows
Table 1
Nucleotide and amino acid substitution in coxsackievirus A9
neutralization-resistant variants
MAb
group
CAV9
variant
Protein Nucleotide
change
Amino acid
change
1 vK3.1 VP3 1938 A-G 69 Arg-Gly
vK3.2 VP3 1917 A-G 62 Thr-Ala
vK3.3 VP3 1917 A-G 62 Thr-Ala
vK3.4 VP3 1917 A-G 62 Thr-Ala
vK3.5 VP3 1917 A-G 62 Thr-Ala
2 vK6.1 VP2 1443 A-G 165 Lys-Glu
vK6.2 VP2 1443 A-G 165 Lys-Glu
vK6.3 VP2 1443 A-G 165 Lys-Glu
vK6.4 VP2 1443 A-G 165 Lys-Glu
vK6.5 VP2 1443 A-G 165 Lys-Glu
vK6.6 VP2 1443 A-G 165 Lys-Glu
vK6.7 VP2 1410 G-A 154 Glu-Lys
vK6.8 VP2 1410 G-A 154 Glu-Lys
vK8.1 VP2 1443 A-G 165 Lys-Glu
vK8.2 VP2 1443 A-G 165 Lys-Glu
vK8.3 VP2 1410 G-A 154 Glu-Lys
vK8.4 VP2 1443 A-G 165 Lys-Glu
vK8.5 VP2 1443 A-G 165 Lys-Glu
vK8.6 VP2 1443 A-G 165 Lys-Glu
vK8.7 VP2 1443 A-G 165 Lys-Glu
3 v4B3 VP2 1159 A-T 70 Lys-Met
Table 2
Recognition of CAV9 or VP1 peptides by hybridoma supernatants or
immune sera by ELISA
Antibody Peptides
p189 p191 CAV9 PBS
MAbs (59 clones) 0.14–0.26a 0.15–0.22 2.10–2.60 0.14–0.24
M-pre-immune 0.09b 0.20 0.20 0.10
M-CAV9 0.70 0.30 2.50 0.10
R-pre-immune 0.20 0.20 0.22 0.15
R-p189 2.60 0.50 1.70 0.30
R-p191 0.38 2.50 0.45 0.18
R-CAV9 0.70 0.40 2.30 0.18
a OD value range.
b OD value (450 nm). (R) rabbit serum; (M) mouse serum.
76 G. Buttinelli et al. / Virology 312 (2003) 74–83
VP2 amino acid 70, targeted by MAb 4B3. The image,
presented for description purposes, is based on the crystal
structure defined for CAV9 by Hendry and co-workers
(Hendry et al., 1999) and does not take into account possible
perturbations induced by the change of the indicated amino
acids. The C-terminal amino acid tail, containing the RGD
motif and missing in the original sequence, was added to
visualize the viral structure involved in integrin binding.
The combination of the front (Fig. 1A) and side (Fig. 1B)
views of the protomer shows that amino acid residues in-
volved in both patterns of resistance to MAb neutralization
are indeed closely related. The approximate distances esti-
mated in the two cases were in fact 13 and 11 Å, respec-
tively, for vK3 and vK6/vK8, in all cases within the span-
ning area of an IgG antibody. Conversely, the distance
between the two pairs of residues as well as residue 70 of
VP2 appeared to be higher, in the order of (25–35) Å,
compatible with the absence of cross-reaction reported be-
tween MAb groups.
A comparison between the capsid proteins of CAV9 and
poliovirus type 1 Mahoney is shown in Fig. 2. The epitopes
identified in CAV9, VP3, and VP2 proteins appear to over-
lap, respectively, the antigenic sites N-AgIII (3b), and N-
AgII (2b), and N-AgIV of poliovirus (Minor et al., 1986;
Minor, 1990).
Protection of infant mice from CAV9 infection by MAbs
The ability of neutralizing MAbs to protect from infec-
tion in vivo was investigated in an infant mouse model of
myositis (Harvala et al., 2002; Hyypia et al., 1993). Prelim-
inary experiments showed that approximately 100 PFU of
CAV9 corresponded to 1 LD50 of CAV9 in infant mice
inoculated ip at day 1 after birth. The age of mice at
challenge appeared to be critical for a timely outcome of
clinical signs and death (not shown); therefore, all protec-
tion experiments were standardized for virus challenge be-
tween 12 and 24 h after birth. Under these conditions,
virtually 100% of mice died between 4 and 5 days after
challenge. As shown in Table 3, treatment with representa-
tive MAbs from all groups proved to be highly effective in
protecting mice from death. In the case of MAb K8, the
calculated protection rate was slightly lower (66.7%) com-
pared to the other MAbs. However, the lower rate essen-
tially reflected the high mortality observed in just one of the
litters (4/4) before day 2, which was likely due to problems
of the dam rather than to an early virus effect.
Discussion
Even though CAV9 and the other Coxackieviruses share
similar biochemical characteristics and three-dimensional
structure with the well-studied poliovirus, knowledge of
their antigenic structure and pathogenic mechanisms is still
incomplete. In particular, the absence of a detailed map of
protective antigenic sites in coxsackieviruses is an obstacle
to developing a safe immunologic prophylaxis against in-
fection with these viruses. In fact, it has been suggested that
CAV9 and CBV4 may cause type I diabetes (Hyoty et al.,
1995; Roivainen et al., 1998), and CBV4 and CBV3 also
may cause miocarditis (Grist et al., 1978; Hovi et al., 1996),
possibly via the elicitation of an antibody or cell-mediated
reaction against tissue antigens due to molecular mimicry of
Fig. 1. Ribbon representation of the CAV9 (Griggs strain) protomer indicating the position of VP3 residues 62 and 69 (yellow spheres), and VP2 residues
154 and 165 (orange spheres) and 70 (violet sphere) identified in neutralization-resistant virus mutants. Views are from the front (A) and the side (B). VP1,
VP2, VP3, and VP4 are colored in blue, green, red, and white, respectively. The C-terminal of VP2 RGD motif is shown in orange.
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some viral proteins (Hyoty et al., 1995; Roivainen et al.,
1998). A vaccine approach should therefore direct the im-
mune response toward specific viral regions in the absence
of antigenic sites involved on harmful reactions that might
be fulfilled by developing recombinant peptide vaccines or
DNA vaccines tailor-suited to present only the sequences
needed to establish protection.
In the case of CAV9, the knowledge of possible anti-
genic sites is to date limited to the studies of Pulli and
co-workers (Pulli et al., 1998a,b), that in particular indicated
the C-terminal end of the capsid protein VP1 as a putative
important epitope eliciting neutralizing antibodies.
Our present study brings additional insight to the knowl-
edge of CAV9 proteins associated with neutralizing anti-
body response, using the established approach of generating
and characterizing monoclonal antibodies toward live virus
in mice. Our data indicate that similarly to polioviruses
CAV9 also induces a strong immune response in mice; in
fact, a single fusion yielded as many as 53 distinct hybrid-
oma clones secreting virus-specific MAbs.
Fig. 2. 3D structure of poliovirus type 1 Mahoney and CAV9 protomers superimposed. Poliovirus Mahoney N-AgIII(3b) (cyan), N-AgII(2b) (yellow), and
N-AgIV (violet) are compared with the epitopes of VP3 (blue) and VP2 (orange and red) identified in CAV9.
Table 3
Protection of newborn mice from CAV9 infection by MAbs
MAb
(group)
No. of
mice
challenged
No. of mice surviving at day: Percent of
protection
1 2 3 4 5 6 7 15
K3 (1) 15 14 14 14 14 14 14 14 14 93.3
K8 (2) 15 14 10 10 10 10 10 10 10 66.7
4B3 (3) 8 8 8 8 8 8 8 8 8 100.0
3ba 5 5 5 5 2 1 0 0 0 0.0
None 12 12 12 12 4 0 0 0 0 0.0
a 3b is a polio-specific MAb non-cross-reacting with CAV9.
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The results of characterization of MAbs according to
their pattern of reactivity with CAV9 neutralization-resis-
tant mutants indicate that a majority of MAbs developed in
this study are directed to VP2, and precisely, to an epitope
which comprises amino acid residues 154 and 165. In fact,
single mutations corresponding to either one of these posi-
tions caused the loss of neutralization by 10 of 18 MAbs
studied. This suggests that VP2 of CAV9 may contain a
reactive antigenic site which conversely was not observed in
the study by Pulli and co-workers (Pulli et al., 1998a) using
hyperimmune sera and peptide scanning. However, studies
conducted with short peptides suffer from the limitation that
peptides do not necessarily share the same spatial confor-
mation as their amino acid sequence counterpart assembled
in the virion, which may be critical for recognition by MAbs
generated with assembled virions. In particular, for the more
studied polioviruses it has been shown that in no case
neutralizing monoclonal antibodies could react with dena-
tured viral proteins in Western blotting, which implies that
neutralization sites are conformation dependent (Minor et
al., 1985, 1986; Page et al., 1988). In this view, our present
approach presents the advantage that naive virions were
used both to prime the immune system and to detect and
characterize the ensuing immune response. A second neu-
tralization epitope of CAV9, recognized by seven of our
MAbs, appears to be located in VP3 between residues 62
and 69. This may be part of the same antigenic site located
by Pulli and colleagues in the N-terminal region of VP3
(Pulli et al., 1998a). Finally, a third epitope was identified
by a single MAb in VP2, residue 70.
Interestingly, the neutralization sites described by our
present MAbs may be closely related to antigenic sites
previously described for polioviruses. In fact, our MAbs K6
and K8 selected mutations in VP2 residues 154 and 165 of
CAV9. The latter in poliovirus is within neutralization site
N-AgII, comprising VP2 residues 164–170 (Minor et al.,
1986; Page et al., 1988; Wiegers et al., 1990). Conversely,
the VP3 moiety of poliovirus site N-AgIII includes among
others residues 58–61, 66, 70–73 (Minor et al., 1986; Page
et al., 1988), while our CAV9 MAb K3 is targeted to VP3
residues 62 and 69. This coincidence at the level of amino
acid sequence also finds correspondence between the pro-
tein tertiary structure of CAV9 and polio capsid proteins,
despite the deletion present in the “puff” region of CAV9
VP2 as compared with polio site 2b (data not shown). The
similarities found between CAV9 and poliovirus are partic-
ularly suggestive, since in poliovirus type 1 these residues
of N-AgIII and N-AgII may be also relevant in the elicita-
tion of mucosal immunity (Fiore et al., 1997). Also the third
epitope identified in VP2 (aa 70) with MAb 4B3 recalls a
known site of poliovirus, namely N-AgIV (aa 72 of VP2,
76, 77, and 79 of VP3).
The computer-assisted 3D localization in the capsid of
the VP2 and VP3 epitopes identified in the present study
corroborates the absence of reactivity between the three
groups of MAbs described. In fact, the calculated distance
between residues 154–165 and 70 of CAV9 VP2 and resi-
dues 62–69 of VP3 approximates (25–35) Å, that is, enough
to consider unlikely that these residues belong to the same
antibody binding site. Conversely, the short distance be-
tween either VP2 residues 154 and 165 or VP3 residues 62
and 69 is consistent with the cross-reactivity exhibited
within these two groups of MAbs.
Combined results of sequence comparison and 3D anal-
ysis confirm that both VP3 and VP2 epitopes appear to be
exposed on the CAV9 virion surface. In particular, residues
3062–3069 are apparently located in the prominent “knob”
structure (residues 58–69 of VP3) characterized by a high
variability among picornaviruses (Hendry et al., 1999),
whereas VP2 amino acids 154–165 reside in the puff re-
gion. This latter encompasses the E–F loops (residues 129–
178), and in poliovirus is implicated in receptor binding
(Hendry et al., 1999). Both regions are therefore well fitted
for the accomplishment of an antiviral effect by bound
antibodies. Also, residue 70 of VP2 is located in the B–C
loop of VP2.
In addition to neutralization in cell cultures, the three
antigenic sites described by our MAb panel may be also
involved in protection from CAV9 infection in vivo. In fact,
three representative MAbs targeting the three VP2 and VP3
epitopes were shown to efficiently reduce mortality in infant
mice challenged with a lethal dose of CAV9. These results
with single epitope-specific antibodies are encouraging in
terms of developing a vaccinal prophylactic approach to
CAV9 infection. Also, they demonstrate the suitability of
the newborn mouse model for studying in detail the molec-
ular basis of the protective immune response to coxsack-
ievirus.
Of the 18 neutralizing MAbs characterized in this study,
none was directed to VP1. This finding is apparently in
contrast with previous reports that CAV9 VP1 displays at
least two epitopes, one of which is probably involved in
neutralization (Pulli et al., 1998a,b). More precisely, these
authors reported that the C-terminus of VP1 contains an
RGD motif that has been related to the ability of the virus to
infect some permissive cells via v3-integrin binding
(Roivainen et al., 1994). In such a case, blocking of this
viral site by an antibody would presumably prevent virus
binding to the cell surface and consequently infection. For
this reason, our hybridomas were screened for neutraliza-
tion both on the RD cell line displaying a second receptor
other than v3-integrin for virus binding and on A549 cells
which present only v3-integrin as receptor for CAV9
(Roivainen et al., 1996). Nonetheless, the use of the latter
cells did not show further neutralizing MAbs in addition to
the ones detected on RD cells, ruling out the possibility that
MAbs to VP1 might have gone undetected due to the pres-
ence of a subsidiary receptor (Roivainen et al., 1996). While
we failed to isolate neutralizing MAbs to VP1, we did
however detect a weak reactivity versus the RGD flanking
region of CAV9 VP1 for the immune mouse serum in a
peptide-based ELISA assay. Identical results were obtained
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by immunizing a rabbit with CAV9. The amino acid se-
quence toward which CAV9 immunization apparently elic-
ited an immune response spans VP1 residues 293 through
302, beginning from the amino acid immediately following
the RGD motif. The lack of reactivity of the same sera with
a second peptide corresponding to VP1 stretch 272–287 also
suggests that the RGD stretch itself is not part of the anti-
body binding site. Our results with peptides confirm those
reported previously by Pulli and co-workers (Pulli et al.,
1998a,b). Although the RGD motif involved in coxsackievi-
rus binding to cells is contiguous to the 293–302 VP1
region, these authors suggested that antibodies targeted to
this peptide would unlikely act by steric hindrance on the
v3-integrin-binding domain of CAV9. In fact, their anti-
peptide antiserum could also neutralize virus growth in RD
cells, which are infected by CAV9 in an RGD-independent
manner (Roivainen et al., 1996). Rather, the authors sug-
gested that interference with uncoating or aggregation of
virions may be the mechanisms by which these specific
antibodies play their role, as previously reported for other
picornaviruses (Hewat and Blaas, 1996; Smith et al., 1993;
Thomas et al., 1985). In FMDV, the RGD sequence has
been shown to be part of a neutralization epitope (Fox et al.,
1989) and, more specifically, to block the antiviral activity
of antibodies preventing FMDV binding to BHK hamster
kidney cells.
Although our findings seem to indicate that CAV9 VP1
may be poorly immunogenic in mice upon parenteral im-
munization, we cannot exclude that this protein may repre-
sent an important viral antigen in neutralization and protec-
tion in vivo. In fact, we presently generated MAbs by
parenteral immunization of adult mice which are not ex-
pected to permit an extensive replication of CAV9 as in the
course of natural infection. Although the procedure we used
has been widely reported for other viruses (Blondel et al.,
1986; Diamond et al., 1985; Greenberg et al., 1983; Minor
et al., 1986; Page et al., 1988), it is possible that a different
route of uptake and processing of the virus may lead to a
different epitope targeting by the immune system. Further
work is therefore needed to address this issue. Also, our
study confirms that mechanisms other than inhibition of
binding to v3-integrin are involved on CAV9 neutraliza-
tion.
In our experiments, no significant cross-reactivity was
observed between different representatives of human picor-
naviruses when the neutralization test was performed with
CAV9 MAbs. Previously, CAV9 rabbit hyperimmune se-
rum was shown to inhibit infectivity of HPEV1, a picorna-
virus sharing a similar RGD motif in VP1 with CAV9
(Joki-Korpela et al., 2000). This phenomenon was not ob-
served with a CAV9 RGD deletion mutant or with CBV4,
which has no RGD motif, suggesting that the antigenic
determinant responsible for the cross-neutralization would
be located in the C-terminus of VP1. In the present work,
MAbs K3, K6, and 4B3 specifically inhibited the growth of
CAV9 and the RGD deletion mutant CAV9-12d, indicating
that the neutralizing effect of these antibodies was directed
toward structures which are separate from antigenic regions
in the VP1 RGD-containing region. Also, the fact that the
growth of HPEV1 was not inhibited by these antibodies
supports this idea.
In conclusion, our study indicates that CAV9 is a potent
stimulator of the antibody-oriented immune response in
mouse that does not react differently than poliovirus. It also
highlights the targeting of VP2 and VP3 CAV9 capsid
proteins by the immune system, more specifically, epitopes
that are spatially related with neutralization sites N-AgII
(2b) and N-AgIII (3b) described for poliovirus. As sug-
gested for poliovirus N-AgII and N-AgIII residues, CAV9
neutralization sites identified herein might also be relevant
in the elicitation of mucosal immunity (Fiore et al., 1997),
therefore, representing a possible ideal target for vaccina-
tion.
Materials and methods
Cells, viruses, and virus-derived peptides
Human rhabdomyosarcoma cells (RD, ATCC) were
grown in Eagle’s minimal essential medium (MEM) sup-
plemented with 10% fetal bovine serum (FBS) at 37°C.
Human lung carcinoma cells (A549, ATCC) were grown in
Ham F12 medium containing 10% FBS. The virus used for
production of monoclonal antibodies was the Griggs strain
of CAV9 (Chang et al., 1989) and was amplified after initial
infection of cells with infectious cDNA. Coxsackieviruses
B1–B6, Echovirus 1 (EV1) Farouk strain, human parecho-
virus 1 (HPEV1) Harris strain (from ATCC), and CAV9-
derived virus mutant presenting deletion in the RGD motif
and its flanking regions (CAV9d12; aa 282–288,
TTVANTH) (Hughes et al., 1995) were used in neutraliza-
tion assays (see below) to test possible cross-reactions of
anti-CAV9 MAbs. Synthetic peptides covering the flanking
regions of the RGD motif of CAV9 VP1, namely PAM 189
(aa 293–302, MSTLNTHGAF) and PAM 191 (aa 272–287,
TDTRKDINTVTTVAQS) (Pulli et al., 1998b), and rabbit
sera elicited against these peptides were used in ELISA
assays (see below).
Virus purification
Lysates from cell cultures infected with CAV9 were
ultracentrifuged at 35,000 rpm in a Beckman Ti35 rotor for
3 h at 4°C. Pellets were resuspended in phosphate-buffered
saline (PBS) and layered onto a 30% sucrose cushion in
PBS. After centrifugation in a Beckman SW 41 rotor at
35,000 rpm for 2 h at 4°C, the virus pellet was further
purified by isopycnic banding in a CsCl gradient using a
Beckman SW 41 rotor at 35,000 rpm for 20 h at 16°C. The
viral band was then resuspended in 1 to 2 ml of PBS,
dialyzed against PBS, and used for either immunization of
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mice or coating of ELISA plates. Virus infectious titers
were determined in cell cultures prior to immunization.
Immunization of mice
Six week-old female BALB/c mice (supplied by Charles
River) were inoculated ip with 500 l of purified CAV9
(containing 105 PFU) in the presence of Freund’s complete
adjuvant. Mice were boosted three times at 3-week intervals
with incomplete adjuvant; approximately 10 days after
boosting, sera from immunized animals were tested for the
presence of neutralizing (Nt) antibody to CAV9. The aver-
age Nt antibody titer was approximately 1:512 after the
fourth injection. Sera were also tested for the presence of
antibodies against synthetic peptides or viruses by ELISA.
Fusion
Mice received a final boost 4 days before fusion, by
intravenous injection of 105 PFU of virus. One of the ani-
mals was sacrificed, and the spleen was resected and pre-
pared for fusion as described previously (Greenberg et al.,
1983). Hybridoma cell supernatants were screened using a
microneutralization test and an ELISA assay (see below).
Selected cultures were cloned at least twice by limiting
dilution using a mouse thymocyte feeder layer, and where
requested, MAbs were amplified in mouse ascites. Deter-
mination of the MAb immunoglobulin class was performed
by ELISA using a mouse antibody isotyping kit (Pierce,
Rockford, IL). IgG MAbs were purified from ascites fluid
by affinity chromatography using protein G (ImmunoPure G
IgG Purification Kit, Pierce) according to the manufactur-
er’s instructions. Concentration of purified immunoglobu-
lins was determined by the Bio-Rad Protein Assay.
Enzyme-linked immunosorbent assay (ELISA)
Microtiter ELISA plates were coated overnight at 4°C
with 50 l/well of purified CAV9 diluted 1:200 in PBS and
blocked with 5% FBS in PBS for 1 h at 37°C. Wells were
incubated with a 1:10 dilution of hybridoma cell superna-
tants in 1% BSA/PBS for 2 h at 37°C. Plates were subjected
to secondary incubation with an anti-mouse IgG (HL)
antibody conjugated with alkaline phosphatase (AP). Reac-
tion was developed with p-nitrophenol phosphate (Sigma
104) in 10 mM diethanolamine, pH 11, and optical densities
were measured at a wavelength of 405 nm, after 1 h incu-
bation at 37°C. For peptide ELISA assays, peptides PAM
189 and PAM 189 and PAM 191 (10 g/ml) were diluted
1:6000 in carbonate buffer (0.04 M, pH 9.6) and incubated
onto ELISA plates overnight at 4°C, and plates were
blocked with buffer containing 5% FBS for 2 h at 37°C.
After washing with PBS–Tween (0.025%; PBS/T), wells
were incubated with rabbit anti-peptide-specific antisera or
negative preimmune sera, diluted 1:1000 in PBS/T or with
hybridoma supernatants, diluted 1:5, for 1 h at 37°C. Sec-
ondary incubation was performed with anti-rabbit or anti-
mouse IgG (HL) HRP-conjugated antibodies diluted
1:100 in PBS/T/FBS for 1 h at 37°C. Reactions were de-
veloped with TMB Kit (Vector), and optical density was
measured as described above.
Neutralization assays
A standard microneutralization assay was used (Weber et
al., 1994). Approximately 100 TCID50 of virus were mixed
with either a 1:10 dilution of hybridoma cell supernatants
for screening of the fusion or serial dilutions of selected
antibodies, and the mixtures were incubated for 60 min at
37°C prior to inoculation onto RD or A549 cells in 96-well
plates. With a similar procedure, antigenic virus variants
(see below) were tested for cross-neutralization by MAbs.
Monolayers were scored for CPE daily for 4 days. Neutral-
izing titers were expressed as the dilution of cell supernatant
or ascites fluid resulting in the absence of CPE in 50% of
replica cultures.
Cross-neutralization of CAV9 hybridoma supernatants
against different human picornaviruses
To study the cross-neutralizing activity of the obtained
MAbs among human picornaviruses, we tested the ability of
representative neutralizing MAbs to inhibit the infectivity of
CAV9, CAV9d12 (VP1 C-terminal deletion mutant), echo-
virus 1 (EV1), and human parechovirus 1 (HPEV1) in RD
and A549 cells. Fifty microliters of undiluted MAb was
combined with an equal amount of virus dilution (100 PFU
of each virus) and incubated for 1 h at 37°C, and 100 l of
mixture was added onto washed cells. Each antibody was
tested in four parallel wells. After 15 min incubation at RT,
the medium was replaced by 0.5% carboxy methyl cellulose
in culture medium. Following incubation at 37°C for 48 h,
the cells were stained with crystal violet prior to counting
the number of plaques.
Isolation of CAV9 antigenic variants
Neutralization-resistant CAV9 variants were selected in RD
cell monolayers by plaquing serial dilutions of virus (107 to 108
PFU) previously neutralized with the selected MAbs (1:100
dilution of ascites fluid), and including the antibody (1:1000) in
the overlay medium during growth. Several single well-devel-
oped viral plaques were picked from each plate and subjected
to at least two further cycles of plaque purification before
cell-culture expansion in antibody-free medium. Identification
of neutralization-escape CAV9 mutants was eventually con-
firmed by neutralization tests. Virus mutants were designated
with the name of the corresponding MAb used for selection
preceded by the type “v.”
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Nucleotide sequencing
The capsid region of CAV9 variants was sequenced by
using RT-PCR. A few microliters of viral suspension were
resuspended in RT buffer containing 20 mM Tris–HCl pH 8.8,
75 mM KCl, and 2.5 mM MgCl2. After heat denaturation at
70°C, genomic RNA was subjected to reverse transcription
and cDNA amplification with a panel of synthetic oligonucle-
otides as primers. Amplified products were purified and se-
quenced by the DyeDeoxy Terminator Cycle Sequencing Kit
(Applied BioSystems, Perkin–Elmer, Foster City, CA) with
the same primers used for amplification. RNA from CAV9
Griggs parental strain was included as control. The sequences
obtained were aligned with the reference strain sequences.
Structural analysis of coxsackievirus A9 antigenic sites
Structural analysis was performed by using the Insight II
molecular modeling package (MSL, San Diego, CA) (Bern-
stein et al., 1977) using the coordinates of the CAV9 re-
ported by Hendry and co-workers (PDB code: 1DM4) (Hen-
dry et al., 1999). To visualize the RGD motif localization,
the structure was integrated with the C-terminal sequence
by a homology modeling approach, based on the crystal
structure of the RGD motif of the foot and mouth disease
virus (FMDV) (PDB CODE: 1QJG) (Hewat et al., 1997).
Comparison of poliovirus and CAV9 antigenic sites was
performed by superimposing the promoter 3D structures.
Poliovirus type 1 Mahoney coordinates reported by Hogle
and co-workers were used (Hogle et al., 1985).
Protection studies in mice
An in vivo model of myositis in the suckling mouse was
used (Harvala et al., 2002; Hyypia et al., 1993). To assess the
activity of MAbs in vivo, a procedure similar to that described
by Pincus et al. (1995) for murine leukemia virus was used.
BALB/c mice within 24 h from birth were injected ip with 50
g of selected purified MAbs in 50 l PBS. After 3 h, mice
were challenged with 50 l of virus suspension containing
approximately 100 LD50 of CAV9. To titrate virus infectivity
in the mouse, preliminary experiments were performed with
serial dilutions of virus and showed that 1 LD50 equaled ap-
proximately 102 PFU. To induce a prolonged presence of MAb
in the body fluids, MAbs were also administered at day 2 and
4. Test mice were followed for up to 15 days after challenge,
and protection was defined as the absence of a fatal outcome.
Values reported represent pooled results from two independent
experiments.
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